A Web-Based Multimedia Resource for Prescription Opiate Treatment: Epidemiological data clearly indicate that the abuse of prescription opiates is a major public health problem. Buprenorphine is an important medication that offers great promise in treating individuals who have become dependent on prescription opiates. It is widely accepted that successful treatment with buprenorphine involves a combination of buprenorphine and psychosocial counseling/therapy support. However, there is growing evidence that many individuals addicted to prescription opiates who are being treated with buprenorphine do not participate in any form of counseling or therapy. Reasons cited for non-participation in counseling and therapy include added cost of such services, difficulty in accessing counseling professionals with knowledge about the use of buprenorphine, and logistical challenges in finding time to attend therapy programs. Eyes of the World Media Group (EOW), in collaboration with UCLA Integrated Substance Abuse Programs (ISAP), proposes to develop an innovative Web-based resource to augment buprenorphine treatment of prescription opiate users. This application proposes to develop Inside Prescription Drug Abuse (IPDA), a Web- based multimedia resource for prescription opiate treatment. IPDA uses recent advances in Internet technology to bring together interactive video modules, streaming video/animation segments, quizzes, an online forum, and other resources in a customized Website that allows participants to control when, where, and how they experience treatment-related content. These media tools will convey engaging, scientifically accurate information, provide behavioral treatment exercises based on cognitive behavioral therapy principles, and promote recovery activities via interactive feedback and engagement tools. The project team will combine the media expertise of EOW led by Emily Meyers, MBA, and Marisa Murgatroyd, MA, with a team of addiction experts from UCLA ISAP led by Larissa Mooney, MD. This team will develop the content, video, and Website applications to create a unique resource for patients in buprenorphine treatment. Data will be collected on the value of the IPDA resource from two important potential consumer groups, buprenorphine-prescribing MDs (N=50) as well as patients (N=50) currently in treatment with buprenorphine. Data will be collected via focus groups, rating scales, and questionnaires on the perceived usefulness of the IPDA resource, the relevance and accuracy of the material presented on the site, the appeal and benefit of the innovative video scenarios, and feedback on pricing, marketing, and promotion efforts. The use of the multimedia Web platform is innovative, and there is evidence of commercial promise with such a product. A Phase II controlled trial evaluation of IPDA would follow a successful Phase I project.
Public Health Relevance: The development of an accessible and cost-effective Web-based resource to augment the buprenorphine treatment of individuals dependent on prescription opiates will improve the treatment response of this patient group and reduce the morbidity and mortality associated with prescription opiate addiction. This intervention allows patients in buprenorphine treatment access to a set of Web-based multi-media resources comprising interactive videos, animations, quizzes, customized feedback tools, and other resources promoting (a) knowledge and skills consistent with the principles of cognitive behavioral therapy, (b) the benefits of buprenorphine, and (c) other important addiction knowledge to support positive recovery activities. If successful, the product has the potential to reduce significant geographic, temporal, and financial barriers to psychosocial support;provide critical behavioral and addiction knowledge;and improve the treatment outcomes of thousands of opioid-dependent individuals.
Thesaurus Terms: 6,14-Ethenomorphinan-7-Methanol, 17-(Cyclopropylmethyl)-Alpha-(1,1-Dimethylethyl)-4,5-Epoxy-18,19-Dihydro-3-Hydroxy-6-Methoxy-Alpha-Methyl-, (5alpha,7alpha(S))-;Aids Virus;Access To Care;Access To Health Care;Access To Healthcare;Accessibility Of Health Care;Acquired Immune Deficiency Syndrome Virus;Acquired Immunodeficiency Syndrome Virus;Addiction, Opiate;Animation;Animation (Pt);Animation [publication Type];Availability Of Health Services;Behavior Conditioning Therapy;Behavior Modification;Behavior Therapy;Behavior Therapy, Cognitive;Behavior Treatment;Behavior Or Life Style Modifications;Behavioral;Behavioral Conditioning Therapy;Behavioral Modification;Behavioral Therapy;Behavioral Treatment;Buprenorphine;Businesses;Clinical Trials, Phase Ii;Cognitive Therapy;Collaborations;Conditioning Therapy;Counseling;Data;Dependence, Opiate;Development;Drug Abuse;Drugs;Epidemiology;Evaluation;Exercise;Exercise, Physical;Eye;Eyeball;Feedback;Focus Groups;Hiv;Htlv-Iii;Health Services Accessibility;Human Immunodeficiency Viruses;Human T-Cell Leukemia Virus Type Iii;Human T-Cell Lymphotropic Virus Type Iii;Human T-Lymphotropic Virus Type Iii;Individual;Internet;Intervention;Intervention Strategies;Knowledge;Lav-Htlv-Iii;Life Style Modification;Lymphadenopathy-Associated Virus;Marketing;Medication;Morbidity;Morbidity - Disease Rate;Mortality;Mortality Vital Statistics;Multimedia;Multimedium;Nida;Nih;Nih Program Announcements;National Institute Of Drug Abuse;National Institutes Of Health;National Institutes Of Health (U.S.);On-Line Systems;Online Systems;Opiate Addiction;Opioid;Participant;Patients;Pharmaceutic Preparations;Pharmaceutical Preparations;Phase;Phase 2 Clinical Trials;Phase Ii Clinical Trials;Price;Program Announcement;Programs (Pt);Programs [publication Type];Psychosocial Assessment And Care;Psychotherapy, Cognitive;Public Health;Questionnaires;Randomized Controlled Trials;Recovery;Research;Research Resources;Resources;Risk Reduction;Services;Site;Stream;Substance Abuse Problem;Technology;Therapy, Cognition;Time;Training;Treatment Outcome;United States National Institutes Of Health;Virus-Hiv;Www;Abuse Of Drugs;Abuse Of Substances;Abuses Drugs;Access To Services;Access To Treatment;Addiction;Animation;Availability Of Services;Base;Behavior Intervention;Behavioral Intervention;Clinical Trial Phase Ii;Cognitive Behavior Intervention;Cognitive Behavior Modification;Cognitive Behavior Therapy;Cognitive Behavioral Intervention;Cognitive Behavioral Modification;Cognitive Behavioral Therapy;Control Trial;Cost;Cost Effective;Design;Designing;Drug /Agent;Drug/Agent;Experience;Health Care Availability;Health Care Service Access;Health Care Service Availability;Health Services Availability;Healthcare Access Availability;Healthcare Service Access;Healthcare Service Availability;Human Immunodeficiency Virus;Improved;Innovate;Innovation;Innovative;Innovative Technologies;Interventional Strategy;Online Computer;Opioid Addiction;Opioid Dependence;Phase 2 Study;Phase 2 Trial;Phase Ii Trial;Prescription Drug Abuse;Prescription Opiate;Pricing;Programs;Protocol, Phase Ii;Psychosocial;Psychosocial Assessment;Psychosocial Care;Psychosocial Studies;Psychosocial Support;Public Health Medicine (Field);Randomized Controlled Study;Response;Skills;Study, Phase Ii;Substance Abuse;Tool;Treatment Response;Web;Web Based;Web Site;World Wide Web
